Comparative Pharmacology
Head-to-head clinical analysis: BROMSITE versus ILEVRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMSITE versus ILEVRO.
BROMSITE vs ILEVRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromsite (bromfenac ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) 1 and 2, thereby reducing prostaglandin synthesis in ocular tissues.
Nepafenac is a prodrug that is metabolized to amfenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis.
1-2 tablets (200-400 mg) orally 3-4 times daily as needed.
1 drop of the 0.3% ophthalmic solution administered to the affected eye(s) four times daily.
None Documented
None Documented
Terminal elimination half-life 12–15 hours; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life of amfenac is approximately 0.7 hours in plasma, but due to prolonged residence in ocular tissues, the clinical effect lasts up to 24 hours with once-daily dosing.
Primarily renal excretion of unchanged drug (~70%) and glucuronide conjugate (~20%); minor biliary/fecal elimination (~10%).
Nepafenac is extensively metabolized, and its active metabolite amfenac is primarily excreted renally (approximately 80% as metabolites, including amfenac glucuronide, and 20% as unchanged drug in urine). Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID